Ozempic

(Semaglutide)

ApprovedPeptide

Semaglutide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used for weight loss in people who are overweight or obese. It works by helping your body use insulin better and reducing your appetite.[2] Ozempic is currently approved and in use across 89 indications[4].[1]

Ozempic is one of 1581 peptide programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

506

Total Trials

Active Trials

1,580

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseApproved

HyperplasiaActive, not recruiting

Metabolic SyndromeApproved

Cirrhosis of LiverActive, not recruiting

ArrhythmiaActive, not recruiting

Cardiovascular DiseaseApproved

Endothelial DysfunctionActive, not recruiting

Klinefelter's SyndromeActive, not recruiting

Methamphetamine DependenceActive, not recruiting

Nicotine DependenceActive, not recruiting

Coronary Artery DiseaseApproved

Approved

HyperplasiaPhase 2

Active, not recruiting

Metabolic SyndromeApproved

Approved

Cirrhosis of LiverPreclinical

Active, not recruiting

ArrhythmiaPhase 3

Active, not recruiting

Cardiovascular DiseaseApproved

Approved

Endothelial DysfunctionApproved

Active, not recruiting

Klinefelter's SyndromePhase 2

Active, not recruiting

Methamphetamine DependencePhase 2

Active, not recruiting

Nicotine DependencePhase 2

Active, not recruiting

Showing 10 of 89 indications

Competition

Competitive Landscape

1400 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

2 2

Duragesic

CCephalon

Preclinical

1 3

Viagra

VViatris Specialty LLC

Preclinical

1 4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Triptorelin Pamoate

Ipsen

Preclinical

2 6

Statin

Bristol-Myers Squibb

Preclinical

1 7

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—8

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

9 9

Sonovue

BBracco Diagnostics, Inc

Preclinical

2 10

AZD5305

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Prostate Cancer

NCT06908694

Post-ApprovalRecruiting

Metabolic Syndrome

NCT06410352

Post-ApprovalActive, not recruiting

Medication

NCT04892199

Phase 2Recruiting

Chronic Kidney Disease

NCT06717698

Q4 2026

Phase 3Active, not recruiting

Body Weight

NCT05567796

Not yet recruiting

Type 2 Diabetes Mellitus

NCT05714683

Clinical

Trials by Indication[1]

Type 2 Diabetes43 trials

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03689374·2,274 enrolled

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06323161·274 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05443191·50 enrolled

Show 40 more trials

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03914326·9,651 enrolled

A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment

Completed· Novo Nordisk logo

Novo Nordisk··NCT06478550·304 enrolled

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03015220·458 enrolled

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02128932·1,089 enrolled

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02461589·706 enrolled

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03989232·961 enrolled

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

Unknown status·KKirsi Pietiläinen·Phase 4·NCT04854083·50 enrolled

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05478252·388 enrolled

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

Recruiting·UUniversity of Washington·Phase 4·NCT05780905·50 enrolled

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

Unknown status·—·Phase 4·NCT05597202·22 enrolled

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Unknown status·SSteno Diabetes Center Copenhagen·Phase 4·NCT04061200·80 enrolled

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

Completed·—·N/A·NCT05078255·61 enrolled

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Enrolling by invitation·SSteno Diabetes Center Copenhagen·Phase 4·NCT06954090·50 enrolled

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06974825·67 enrolled

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 4·NCT05303857·107 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06083675

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Not yet recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07400107·1,000 enrolled

A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

Completed· Novo Nordisk logo

Novo Nordisk··NCT05468632·314 enrolled

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT03596450·1,278 enrolled

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02773381·15 enrolled

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02212067·87 enrolled

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05394519·1,200 enrolled

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06260722·1,250 enrolled

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Completed· Novo Nordisk logo

Novo Nordisk··NCT06351748·34,238 enrolled

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02827708·324 enrolled

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05950516·478 enrolled

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03136484·788 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02054897·388 enrolled

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05649137·512 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05444153

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT04094415·581 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02305381·397 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05443334·465 enrolled

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03018028·243 enrolled

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

Completed· Novo Nordisk logo

Novo Nordisk··NCT05716724·288 enrolled

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02692716·3,183 enrolled

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02648204·1,201 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01930188·1,231 enrolled

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT05035082·1,020 enrolled

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk··NCT06507475·209 enrolled

Semaglutide33 trials

Real-world Health Outcomes in Canadian Patients Using Semaglutide

Completed·LLMC Diabetes & Endocrinology Ltd.··NCT04175665·1,133 enrolled

Semaglutide and Intestinal Iron Absorption

Completed·UUniversity Hospital Dubrava·N/A·NCT06629688·51 enrolled

Genetics of the Acute Response to Oral Semaglutide

Recruiting·MMedical University of Bialystok·N/A·NCT05340868·1,000 enrolled

Show 30 more trials

The Effect of Semaglutide on Bone Health

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 4·NCT07165158·150 enrolled

Semaglutide vs Sitagliptin

Unknown status·UUniversity Health Network, Toronto·Phase 4·NCT05195944·140 enrolled

Semaglutide and Vascular Regeneration

Unknown status·CCanadian Medical and Surgical Knowledge Translation Research Group·Phase 4·NCT05870462·100 enrolled

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05227196·546 enrolled

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

Completed·UUniversity of Colorado, Denver·Phase 2/3·NCT03919929·60 enrolled

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

Not yet recruiting·BBostal Drug Delivery Co., Ltd·Phase 1·NCT06422624·14 enrolled

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05784402·264 enrolled

Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

Completed·HHospital Israelita Albert Einstein··NCT06154486·30 enrolled

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

Unknown status·—·Phase 1·NCT05249881·300 enrolled

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Terminated·SSansum Diabetes Research Institute·Phase 4·NCT04938388·12 enrolled

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03598621·68 enrolled

Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06387199·26 enrolled

Semaglutide in Auto-HSCT

Not yet recruiting·KKlaus Gottlob Müller·Phase 2·NCT06449625·40 enrolled

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05046873·16 enrolled

The Effect of Weekly Semaglutide Treatment on Energy Expenditure

Completed·SShenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences·N/A·NCT06390501·60 enrolled

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Recruiting·AActimed Therapeutics Ltd·Phase 2·NCT07101939·120 enrolled

A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02845219·25 enrolled

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02172313·78 enrolled

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05498610·24 enrolled

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT04189848·104 enrolled

16-week Flexible vs. 8-week Semaglutide Titration

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT04447859·100 enrolled

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05890976·200 enrolled

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Not yet recruiting·—·Phase 4·NCT07483801·112 enrolled

Semaglutide Therapy for Alcohol Reduction - Tulsa

Completed·OOklahoma State University Center for Health Sciences·Phase 2·NCT05891587·80 enrolled

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02146079·44 enrolled

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02064348·168 enrolled

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02231684·42 enrolled

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02557620·113 enrolled

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02022254·24 enrolled

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02161588·48 enrolled

Type 2 Diabetes Mellitus12 trials

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04515849·248 enrolled

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02863419·711 enrolled

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03021187·731 enrolled

Show 9 more trials

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

Not yet recruiting·—·N/A·NCT06555146·15 enrolled

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruiting· Novo Nordisk logo

Novo Nordisk··NCT05714683·600 enrolled

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Not yet recruiting·PProGen. Co., Ltd.·Phase 2·NCT07187856·80 enrolled

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03951753·117 enrolled

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 4·NCT06475586·30 enrolled

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Unknown status·RRenJi Hospital·N/A·NCT05779644·300 enrolled

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Unknown status·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06256549·272 enrolled

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

Completed·UUniversity Medical Centre Ljubljana·Phase 3·NCT06489457·25 enrolled

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02849080·504 enrolled

Obesity11 trials

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Recruiting·KKailera·Phase 3·NCT07284979·1,200 enrolled

Tailoring Obesity Treatment Trial

Suspended·EEsbjerg Hospital - University Hospital of Southern Denmark·Phase 2/3·NCT06619015·40 enrolled

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Enrolling by invitation·MMayo Clinic·Phase 4·NCT07057310·30 enrolled

Show 8 more trials

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05236517·60 enrolled

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT04969939·120 enrolled

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06131437·809 enrolled

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06745284·60 enrolled

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT05579249·500 enrolled

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07081178·555 enrolled

The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT04263415·30 enrolled

Overweight9 trials

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04187300·68 enrolled

Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

Recruiting·FFundacion Dexeus·Phase 4·NCT07242534·62 enrolled

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04102189·201 enrolled

Show 6 more trials

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03548987·902 enrolled

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05822830·751 enrolled

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04940078·40 enrolled

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03811574·401 enrolled

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03693430·304 enrolled

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03600480·96 enrolled

68 more indications

Weight loss6 trials

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Recruiting·MMcMaster University·Phase 4·NCT06852391·74 enrolled

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06780449·400 enrolled

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06299098·1,005 enrolled

Show 3 more trials

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Not yet recruiting·BBiophytis·Phase 2·NCT07411378·164 enrolled

WEgovy Real World Assessment of Weight Loss in Korea

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07280221·500 enrolled

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Completed·HHillel Yaffe Medical Center··NCT07043361·5,300 enrolled

Type 1 Diabetes4 trials

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Recruiting·UUniversity of Washington·Phase 2·NCT05822609·60 enrolled

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Recruiting·UUniversity of Colorado, Denver·Phase 3·NCT05819138·60 enrolled

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Recruiting·YYale University·Phase 2·NCT06411210·54 enrolled

Show 1 more trial

ADJUnct Semaglutide Treatment in Type 1 Diabetes

Completed·—·Phase 2·NCT05537233·115 enrolled

Fatty Liver Disease3 trials

GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

Not yet recruiting·IInsel Gruppe AG, University Hospital Bern·N/A·NCT06546384·64 enrolled

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03987451·71 enrolled

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06884293·470 enrolled

Atrial Fibrillation3 trials

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Recruiting·UUniversity of Chicago·Phase 3·NCT06499857·200 enrolled

DUTCH Weight Control in Atrial Fibrillation Study

Recruiting·RRijnstate Hospital·Phase 4·NCT06184633·280 enrolled

Semaglutide to Reduce Atrial Fibrillation Burden

Suspended·SSan Francisco Veterans Affairs Medical Center·Phase 4·NCT05209165·132 enrolled

Cardiovascular3 trials

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

Recruiting·—··NCT06301191·50 enrolled

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Completed·—··NCT07096063·887,132 enrolled

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

Enrolling by invitation·—·Phase 4·NCT06959784·142 enrolled

Drug2 trials

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00851773·84 enrolled

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

Completed·VVivani Medical, Inc·Phase 1·NCT05670379·24 enrolled

Body Weight2 trials

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05567796·3,400 enrolled

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05813925·331 enrolled

Cocaine Use Disorder2 trials

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT07227948·75 enrolled

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06691243·40 enrolled

Chronic Kidney Disease2 trials

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06717698·465 enrolled

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06131372·626 enrolled

Kidney Transplant2 trials

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05938712·20 enrolled

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Terminated·GGeisinger Clinic·Phase 3·NCT04741074·15 enrolled

Non-Alcoholic Fatty Liver Disease2 trials

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Recruiting·YYale University·Phase 2·NCT05067621·60 enrolled

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04216589·51 enrolled

Prostate Cancer2 trials

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Recruiting·HHamilton Health Sciences Corporation·Phase 4·NCT06908694·20 enrolled

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Recruiting·—·Phase 2·NCT07202247·60 enrolled

Alcohol Use Disorder2 trials

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Recruiting·YYale University·Phase 2·NCT07040592·30 enrolled

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

Not yet recruiting·VVA Office of Research and Development·Phase 3·NCT07218354·438 enrolled

GLP-11 trial

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01572753·161 enrolled

Double-blind1 trial

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01766245·28 enrolled

Trichotillomania1 trial

Semaglutide (Wegovy) Treatment for Trichotillomania

Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07282769·10 enrolled

Psoriasis1 trial

Effect of Semaglutide in Patients With Psoriasis and Obesity

Recruiting·TThe University of Hong Kong·Phase 3·NCT06937060·14 enrolled

Ischemic stroke1 trial

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

Recruiting·—·Phase 2·NCT05630586·380 enrolled

Concentration1 trial

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05689099·20 enrolled

Medication1 trial

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Active, not recruiting·AAnders Fink-Jensen, MD, DMSci·Phase 4·NCT04892199·104 enrolled

Menopause1 trial

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05153564·27 enrolled

Diabetes Mellitus1 trial

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

Recruiting·MMedanta, The Medicity, India·N/A·NCT06060392·50 enrolled

Alcoholic Fatty Liver Disease1 trial

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04944992·145 enrolled

Liver Transplant1 trial

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Recruiting·VVirginia Commonwealth University·Phase 2·NCT05424003·50 enrolled

Oral1 trial

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06642584·90 enrolled

Clinical Trial1 trial

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05232708·18 enrolled

Obese Patients1 trial

Semaglutide Use in Elderly Obese Patients

Completed·SState University of New York at Buffalo·Phase 2·NCT05302596·16 enrolled

ART1 trial

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05129891·384 enrolled

Opioid Use Disorder1 trial

GLP-1R Agonist Treatment for Opioid Use Disorder

Recruiting·MMilton S. Hershey Medical Center·Phase 2·NCT06548490·200 enrolled

Treatment1 trial

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Recruiting·WWoman's·Phase 4·NCT04873050·102 enrolled

Lung Disease1 trial

Feasibility of Semaglutide in Advanced Lung Disease

Recruiting·UUniversity of Pennsylvania·Phase 1/2·NCT05746039·8 enrolled

Cognition1 trial

Semaglutide and Cognition in Healthy Volunteers

Completed·UUniversity of Oxford·N/A·NCT06363487·70 enrolled

PreDiabetes1 trial

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Completed·JJan Frystyk·Phase 2·NCT05193578·154 enrolled

Tics1 trial

Pharmacogenetics of Response to GLP1R Agonists

Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT05071898·600 enrolled

Systemic Scleroderma1 trial

Subcutaneous Semaglutide in Systemic Scleroderma

Recruiting·SSecond Xiangya Hospital of Central South University·Phase 1·NCT06149260·10 enrolled

Polycystic Ovary Syndrome1 trial

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Recruiting·PPeking University First Hospital·Phase 4·NCT05702905·75 enrolled

Endothelial Dysfunction1 trial

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Completed·GGeneral and Teaching Hospital Celje·Phase 4·NCT05857085·90 enrolled

Non-Alcoholic Steatohepatitis1 trial

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05016882·698 enrolled

Metabolic Syndrome1 trial

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Recruiting·UUniversity Medical Center, Kazakhstan·Phase 4·NCT06410352·220 enrolled

Renal Impairment1 trial

Effect of Renal Impairment on the Pharmacokinetics of NN9535

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00833716·62 enrolled

Biomarkers1 trial

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

Recruiting·FFederico II University·Phase 4·NCT07314684·80 enrolled

Klinefelter Syndrome1 trial

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Recruiting·GGeorgios Papadakis·Phase 3·NCT05586802·150 enrolled

Probiotic Intervention1 trial

Probiotic Intervention on Body Weight

Recruiting·CChinese Academy of Sciences·N/A·NCT06989177·140 enrolled

Parkinson's Disease1 trial

GLP1R in Parkinson's Disease

Unknown status·OOslo University Hospital·Phase 2·NCT03659682·120 enrolled

Cardiovascular Disease1 trial

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Recruiting·SSteno Diabetes Center Copenhagen·Phase 3·NCT06082063·2,000 enrolled

Weight Change1 trial

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

Unknown status·HHuashan Hospital·Phase 4·NCT05616052·80 enrolled

Hepatitis1 trial

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05877547·381 enrolled

Hyperplasia1 trial

Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05829460

Bipolar Disorder1 trial

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Recruiting·MMayo Clinic·Phase 4·NCT07213466·100 enrolled

Methamphetamine1 trial

Glutide for Ending Methamphetamine

Not yet recruiting·SSan Francisco Department of Public Health·Phase 2·NCT07204249·162 enrolled

Schizophrenia1 trial

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

Recruiting·CCentre for Addiction and Mental Health·N/A·NCT05333003·92 enrolled

Metabolic Disease1 trial

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Withdrawn·CCorEvitas··NCT06354101

Children1 trial

Promoting Healthy Children and Youth

Not yet recruiting·UUniversity of Minnesota·Phase 4·NCT06977438·1,020 enrolled

Major Depressive Disorder1 trial

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04466345·72 enrolled

Insulin Secretion1 trial

Exercise and GLP-1 RA on Insulin Secretion

Unknown status·UUniversity of Copenhagen·N/A·NCT04383197·30 enrolled

Stroke1 trial

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Completed·—·Phase 2·NCT05920889·140 enrolled

Fibrosis1 trial

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Unknown status·UUniversity of California, San Diego·Phase 2·NCT06005012·120 enrolled

Women's Health1 trial

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Not yet recruiting·UUniversity of Colorado, Denver·Phase 2/3·NCT06975111·200 enrolled

Tobacco Use1 trial

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

Recruiting·UUniversity of Oklahoma·Phase 4·NCT06986993·40 enrolled

Heart Failure1 trial

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Completed·—··NCT06914102·58,387 enrolled

Endometrial Cancer1 trial

SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer

Not yet recruiting·HHospital Universitari de Bellvitge··NCT07462663·82 enrolled

Atorvastatin1 trial

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02243098·31 enrolled

Polycystic Ovarian Syndrome1 trial

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Withdrawn·MMethodist Health System·Phase 1·NCT06222437

Sarcopenia1 trial

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Not yet recruiting·EEmory University·Phase 3·NCT07428746·20 enrolled

Dapagliflozin1 trial

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05429593·152 enrolled

Chronic1 trial

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Completed·VVeru Inc.·Phase 2·NCT06282458·168 enrolled

Albuminuria1 trial

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

Completed·UUniversity Medical Center Groningen·Phase 3·NCT04889183·125 enrolled

Unspecified3 trials

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

Unknown status·UUniversity of Nottingham·Phase 4·NCT05606471·45 enrolled

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01619345·27 enrolled

Special Use - Results Surveillance on Long-term Use With Wegovy®

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT06283667·1,000 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 5, 2017

OZEMPIC

NDA NDA209637

Jun 4, 2021

WEGOVY

NDA NDA215256

Dec 9, 2024

RYBELSUS

NDA NDA213051

Dec 22, 2025

WEGOVY

NDA NDA218316

Sources

References

[1]
ClinicalTrials.gov — 506 trial records for Semaglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Ozempic drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Semaglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Semaglutide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA218316). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Ozempic. U.S. Food & Drug Administration.
[7]
PubMed — 7 publications indexed for Semaglutide. U.S. National Library of Medicine.
[8]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: GLP-1 Receptor Agonist[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: Novo Nordisk

Patent Landscape[6]

Patent Cliff

Jul 17, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10357616Jan 20, 2026

9616180Jan 20, 2026

9861757Jan 20, 2026

10376652Jan 20, 2026

9108002Jan 20, 2026

36 more patents

8536122Mar 20, 2026

9775953Jul 17, 2026

10220155Jul 17, 2026

11097063Jul 17, 2026

8920383Jul 17, 2026

RE46363Aug 3, 2026

9687611Feb 27, 2027

9457154Sep 29, 2027

8129343Dec 5, 2031

10960052Dec 16, 2031

10086047Dec 16, 2031

9278123Dec 16, 2031

11382957Dec 16, 2031

9132239Feb 1, 2032

11759501Mar 15, 2033

10933120Mar 15, 2033

11759502Mar 15, 2033

11759503Mar 15, 2033

12594326Mar 15, 2033

11033499Jun 19, 2033

9764003Jun 21, 2033

10335462Jun 21, 2033

10278923May 2, 2034

12239739May 2, 2034

12514822May 2, 2034

12569543Apr 28, 2037

11752198Aug 24, 2038

12214017Aug 24, 2038

10888605Aug 24, 2038

12295988Oct 10, 2038

12551536Oct 10, 2038

12029779Oct 10, 2038

11833248Feb 1, 2039

12396953Feb 1, 2039

11478533May 13, 2040

11318191Feb 17, 2041

Key Publications[7]

Semaglutide in Chronic Kidney Disease: FLOW Trial Results

N Engl J MedMay 24, 2024DOI: 10.1056/NEJMoa2403347

Semaglutide and MASH: Phase 3 Histological Outcomes

N Engl J MedMar 14, 2024DOI: 10.1056/NEJMoa2311203

Oral Semaglutide Versus Injectable GLP-1 Receptor Agonists: A Systematic Review

Lancet Diabetes EndocrinolOct 15, 2023DOI: 10.1016/S2213-8587(23)00263-1

Semaglutide Effects on Heart Failure Outcomes in Obesity: SELECT Trial

N Engl J MedDec 28, 2022DOI: 10.1056/NEJMoa2215256

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

N Engl J MedNov 10, 2022DOI: 10.1056/NEJMoa2215760

Once-Weekly Semaglutide in Adults with Overweight or Obesity

N Engl J MedJun 2, 2022DOI: 10.1056/NEJMoa2206038

Semaglutide 2.4 mg and Cardiometabolic Risk Reduction: STEP Program Results

JAMAFeb 10, 2021DOI: 10.1001/jama.2021.1831